Where tablet manufacture is specified, the liquid free-thiol is pre-adsorbed onto fumed silica at a ratio of 1 : 2.5 w/w before addition to the direct-compression blend. Mercaptoethanol Veterinary Grade API has a density of 1.114 g/mL at 25 °C, a boiling point of 157 °C at 1 atm, and full miscibility with water; direct liquid addition to a tablet matrix is therefore impractical without a solid carrier. The adsorbed premix is conditioned at 20–25 °C and RH ≤ 30 % for 6 h to reduce free liquid migration. Tablet core loading is maintained between 0.08 % w/w and 0.35 % w/w because loadings above 0.5 % w/w produce punch sticking on a 10-station rotary compression machine. A direct-compression blend of silicified microcrystalline cellulose, mannitol and pregelatinised starch is lubricated with sodium stearyl fumarate at 1.0 % w/w; magnesium stearate is avoided because its hydrophobic film prolongs disintegration in this silica-adsorbed system. Compression force is held at 8–14 kN, with an upper boundary of 18 kN, because higher forces induce capping at the interface between the silica carrier and the surrounding excipient matrix. Tablet hardness is controlled at 60–90 N, friability is held below 1.0 % according to USP <1216>, and disintegration time is specified as <15 min in water at 37 °C according to USP <701>. The terminal product is a 6 mm round biconvex tablet with a mass of 220 mg. Batch release includes assay by GC-FID for free-thiol content and uniformity of dosage units according to USP <905> under 21 CFR 211.165.

What Limits Aqueous Injection Stability When Mercaptoethanol Is Present at 0.1 % w/v?

Aqueous injectable formulations impose the narrowest dissolved-oxygen envelope. The vehicle is composed of citrate buffer at pH 6.0–6.5, sodium chloride 0.8 % w/v, and edetate disodium 0.01 % w/v as a transition-metal chelator. Dissolved oxygen is reduced to <0.1 mg/L by nitrogen sparging through a 0.22 μm sterilising-grade filter before the thiol is charged. The solution is filtered through a 0.22 μm polyvinylidene fluoride membrane into sterile Type I borosilicate vials with chlorobutyl rubber stoppers; headspace oxygen is displaced with filtered nitrogen to <1.0 % residual. Terminal steam sterilisation at 121 °C is generally not specified because thiol-disulfide exchange accelerates at elevated temperature and can generate subvisible particulate matter; if a sterility assurance level of 1 × 10⁻⁶ is required, aseptic processing under EU GMP Annex 1 is used. The terminal product is a 50 mL multidose vial containing 1.0 mg/mL mercaptoethanol in a nitrogen-blanketed solution. Batches are tested for visible particulates according to USP <790>, bacterial endotoxins according to USP <85>, and subvisible particulate matter according to USP <788>. Residual oxygen is measured by membrane polarography on-line; a drift above 0.3 mg/L after filling has been observed on lines where vacuum stoppering is not sequenced within 4 s of nitrogen purge. Stainless steel contact surfaces are passivated with citric acid 5 % w/v for 8 h at 70 °C to reduce iron-catalysed thiol oxidation.

Gelatin Capsule Fill Matrix and Thiol-Induced Shell Crosslinking Risk

For encapsulated products, the choice of shell polymer is determined by aldehyde content rather than water activity. Mercaptoethanol reacts with aldehyde impurities in gelatin at neutral pH, producing visible pellicle formation and delayed shell dissolution; hypromellose capsule shells are therefore specified for this thiol. The fill is prepared by adsorbing the liquid API onto calcium silicate at a ratio of 1 : 2.5 w/w, yielding a free-flowing powder with moisture content ≤2.0 % by Karl Fischer titration according to USP <921> Method Ia. Fill weight in a size 3 capsule is 180 mg, delivering 0.15–0.30 mg mercaptoethanol per unit. Encapsulation is conducted in an RH 25–30 % suite at 60,000 capsules/h on a rotary dosator machine; vacuum settings above 0.6 bar have been observed to compact the silica carrier and cause weight variation exceeding 3.0 %. The shell is banded with hypromellose to prevent leakage. Dissolution testing employs USP <711> Apparatus 2 with 900 mL water at 37 °C and paddle speed 50 rpm; release of not less than 80 % is expected within 45 min. The terminal product is a white opaque hypromellose capsule, 15.8 mm closed length, packed in aluminium-PVC blister. Release testing includes USP <905> and moisture vapour transmission according to USP <671>. Batch failures associated with gelatin shell crosslinking are eliminated by the hypromellose shell system but require that no aldehyde-containing printing ink is used on the capsule surface.

Powdered oral mixtures require an anhydrous carrier because the thiol group undergoes rapid oxidative dimerisation when water activity exceeds 0.4 aw. Mercaptoethanol Veterinary Grade API is added to mannitol at a ratio of 1 : 50 w/w in a V-blender operating at 25 rpm for 15 min; the liquid is pre-adsorbed onto fumed silica before blending to prevent agglomerate formation. The blend is discharged into foil laminate sachets with nitrogen flushing to an oxygen headspace <1.0 %; seal integrity is verified by vacuum leak test at -0.4 bar. The terminal product is a 5 g sachet containing 100 mg mercaptoethanol, intended for reconstitution in 1 L drinking water. Uniformity of powder is tested according to USP <905>, and impurity profiling uses HPLC-UV at 240 nm for the disulfide dimer. Published data for oxidative dimerisation rate in dry blends at 25 °C/60 % RH is limited; therefore, real-time stability studies are conducted with open-dish and packaged configurations. On production lines, segregation of the silica-adsorbed thiol from mannitol occurs if the V-blender fill exceeds 60 % of vessel volume or if the sachet filling hopper is vibrated above 1.5 mm amplitude. Batches with loss on drying >2.0 % are rejected due to caking and discoloration.

When Granulated Premix Contact Time Exceeds 45 Minutes

In medicated feed applications, the liquid thiol is first adsorbed onto silica at 1 : 3 w/w and then dispersed on ground corn cobs to form a free-flowing premix. The inclusion rate is 2 kg premix per 1,000 kg finished feed; the thiol concentration in the premix is 5 % w/w. Mixing is performed in a ribbon blender at 75 % fill volume for 20 min; shorter mixing times leave assay coefficients of variation above 5 % because the silica-adsorbed thiol does not migrate out of the central dead zone. The premix is then blended into complete feed and pelleted at conditioning temperature ≤75 °C and retention time 30–45 s. Thermal degradation during pelleting is assessed by comparing assay before and after the conditioner; if loss exceeds 15 %, the conditioning steam pressure is reduced from 4 bar to 2.5 bar. The terminal product is a pelleted feed containing 0.1 % w/w mercaptoethanol, packaged in 25 kg woven polypropylene bags with an inner polyethylene liner. Compliance is anchored to 21 CFR 558.5 and EU Regulation 1831/2003 for feed additives; assay homogeneity is evaluated by taking 12 core samples from the mixer and calculating relative standard deviation. Batch-to-batch variance has been observed when ambient humidity exceeds 60 % RH; under these conditions the carrier moisture increases and the premix loses flowability, causing bridging in the dosing screw.

High-Shear Wet Granulation Parameters for Mercaptoethanol-Loaded Granules

Wet granulation produces a dose-dispensing intermediate for oral drenching. The binder solution is prepared by dissolving povidone K30 at 2.0 % w/w in purified water and cooling to 25 °C before the thiol is added at a ratio of 1 : 20 w/w to binder solution. Mannitol and microcrystalline cellulose are dry-mixed in a high-shear granulator at impeller speed 200 rpm and chopper speed 1,500 rpm for 5 min; the binder solution is sprayed over 90 s. Wet massing continues for 60–90 s; extended massing beyond 120 s generates torque spikes above 8 N·m on a 10 L laboratory granulator and produces oversize granules above 850 μm. The wet granules are dried in a fluid bed at inlet air temperature 45 °C to loss on drying ≤2.5 %. Dried granules are screened through 850 μm and retained on 250 μm; bulk density is controlled between 0.56 g/mL and 0.68 g/mL. The terminal product is a 10 g foil sachet of granules containing 50 mg mercaptoethanol, reconstituted in 50 mL water before oral administration. Dissolution testing is performed on the reconstituted granule suspension using USP <711> Apparatus 2 at 75 rpm; release is expected to exceed 85 % within 30 min. Uniformity of dosage units is evaluated according to USP <905>, and residual povidone content is determined by SEC-UV if required. The main line failure mode is sieve blinding when loss on drying exceeds 3.0 %, causing loss of yield and erratic fill weight in the sachet line.

Solutions for drench administration place the thiol in direct contact with water, propylene glycol and weak acid buffers; stability is therefore governed by pH and headspace oxygen. The formula uses propylene glycol 20 % v/v, citric acid buffer at pH 4.0–5.0, edetate disodium 0.01 % w/v, and mercaptoethanol at 5–10 % w/v. pH below 4.0 increases the volatile free-thiol odour, while pH above 5.0 accelerates dimer formation; the thiol-disulfide redox potential shifts as the thiolate anion becomes predominant above the pKa of approximately 9.6. The solution is filled under nitrogen into amber high-density polyethylene bottles with child-resistant closures; fill volume is 100 mL. Dissolved oxygen is not allowed to exceed 0.5 mg/L at the filling nozzle, measured by optical oxygen probe. The terminal product is an oral drench delivering 500 mg or 1,000 mg mercaptoethanol per bottle. Release testing includes pH according to USP <791>, assay by GC-FID, and microbial limits under USP <61> and USP <62>. Stability testing at 25 °C/60 % RH and 30 °C/65 % RH is conducted in accordance with VICH GL3; open-bottle in-use studies are required because repeated headspace opening can raise dissolved oxygen above the limit within 14 days. Published data for long-term drench stability at 40 °C is limited; forced-degradation studies using hydrogen peroxide 0.1 % w/v are used to identify dimer and sulfenic acid intermediates by LC-MS.